Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, 610041, China.
Department of pathology, West China Hospital, Sichuan University, Chengdu, China.
BMC Cancer. 2018 Mar 12;18(1):278. doi: 10.1186/s12885-018-4196-x.
Microvascular invasion (MVI) is well established as a negative prognostic factor for hepatocelluar carcinoma (HCC). However, its prognostic value in different subgroups of Barcelona Clinical Liver Cancer (BCLC) stages remains to be elucidated.
Four hundred fifty-eight MVI-negative and 204 MVI-positive patients who underwent hepatectomy were retrospectively analyzed. After propensity score matching (PSM) analysis, 187 pairs of matched patients were generated. Long-term survival was compared by the Kaplan-Meier method.
Patients with MVI commonly had more advanced tumors. All the patients with MVI had significantly worse survival rate compared to the patients without MVI before and after PSM(p < 0.001). In the subgroup analysis, BCLC stage A HCC patients without MVI had better prognosis than those with MVI before and after PSM (p < 0.001 and p = 0.024). For BCLC stage B HCCs, long-term survival was significantly better for patients without MVI before PSM(p = 0.001). However, the overall survival (OS) rate was comparable between both groups after PSM (p = 0.682), although MVI-positive group had a higher rate of recurrence (p = 0.011).. Surgery type, satellite lesions, tumor size, and serum ALT level were statistically significant factors associated with survival in MVI-positive group. Tumor number, tumor size and neutrophil to lymphocyte ratio (NLR) were predictors of survival in MVI-negative group.
Its prognostic value in different subgroups of BCLC stages differed. MVI is an independent predictor of prognosis in patients with BCLC stage A. For BCLC stage B HCCs, MVI-positive group had poor prognosis through more advanced HCCs.
微血管侵犯(MVI)已被确立为肝细胞癌(HCC)的一个负性预后因素。然而,其在巴塞罗那临床肝癌(BCLC)分期的不同亚组中的预后价值仍需阐明。
回顾性分析了 458 例 MVI 阴性和 204 例 MVI 阳性接受肝切除术的患者。通过倾向评分匹配(PSM)分析后,生成了 187 对匹配患者。采用 Kaplan-Meier 法比较长期生存率。
MVI 阳性患者的肿瘤通常更晚期。所有 MVI 阳性患者的生存率均明显低于 MVI 阴性患者,无论是否进行 PSM(均 P<0.001)。亚组分析显示,BCLC 期 A HCC 患者中 MVI 阴性者的预后优于 MVI 阳性者,无论是否进行 PSM(均 P<0.001 和 P=0.024)。对于 BCLC 期 B HCC,未进行 PSM 时 MVI 阴性患者的长期生存率明显更好(P=0.001)。但是,PSM 后两组之间的总生存率(OS)相当(P=0.682),尽管 MVI 阳性组的复发率更高(P=0.011)。手术类型、卫星病灶、肿瘤大小和血清 ALT 水平是 MVI 阳性组生存的统计学显著相关因素。肿瘤数量、肿瘤大小和中性粒细胞与淋巴细胞比值(NLR)是 MVI 阴性组生存的预测因素。
其在 BCLC 分期的不同亚组中的预后价值不同。MVI 是 BCLC 期 A 患者预后的独立预测因素。对于 BCLC 期 B HCC,MVI 阳性组的 HCC 更晚期,预后不良。